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Abstract: Antibodies against programmed death-1 (PD-1), and its ligand, (PD-L1) have been
approved recently for the treatment of small-cell lung cancer (SCLC). Although there are previous
reports that addressed PD-L1 detection on tumour cells in SCLC, there is no comprehensive
meta-analysis on the prevalence of PD-L1 expression in SCLC. We performed a systematic search
of the PubMed, Cochrane Library and EMBASE databases to assess reports on the prevalence
of PD-L1 expression and the association between PD-L1 expression and overall survival (OS).
This meta-analysis included 27 studies enrolling a total of 2792 patients. The pooled estimate of PD-L1
expression was 26.0% (95% CI 17.0–37.0), (22.0% after removing outlying studies). The effect size was
significantly heterogeneous (I2 = 97.4, 95% CI: 95.5–98.5, p < 0.0001).Positive PD-L1 expression was a
favourable prognostic factor for SCLC but not statistically significant (HR = 0.86 (95% CI (0.49–1.50),
p = 0.5880; I2 = 88.7%, p < 0.0001). Begg’s funnel plots and Egger’s tests indicated no publication
bias across included studies (p > 0.05). Overall, there is heterogeneity in the prevalence of PD-L1
expression in SCLC tumour cells across studies. This is significantly moderated by factors such as
immunohistochemistry (IHC) evaluation cut-off values, and assessment of PD-L1 staining patterns as
membranous and/or cytoplasmic. There is the need for large size, prospective and multicentre studies
with well-defined protocols and endpoints to advance the clinical value of PD-L1 expression in SCLC.
Keywords: programmed death ligand-1; small-cell lung cancer; meta-analysis
1. Introduction
Lung cancer is the principal cause of cancer-associated mortality globally [1]. Small-cell lung
cancer (SCLC) is a devastating subtype of lung cancer that accounts for about 13–15% of all primary
cancers of the lung [2]. SCLC has one of the highest mutation rates and is strongly associated with
a history of smoking. It is usually diagnosed by bronchoscopic biopsy based on histopathological
features and selected neuroendocrine markers [3]. Patients diagnosed with SCLC are staged as an
extensive disease (ED) or limited disease (LD) appertaining primarily to the spread of metastatic
disease outside the thorax and approximately 70–75% present with an extensive-stage disease at the
time of diagnosis [4].
SCLC patients demonstrate better response rates with the current first-line treatments that include
platinum-based chemotherapy. However, relapse occurs rapidly in most patients and with the
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development of acquired drug resistance [5]. The prognosis of SCLC patients continues to be poor
with an estimated 5% overall 5-year survival rate [6]. Among the SCLC patients diagnosed with
LD, the median overall survival(OS) is 16–24 months with a 2-year survival rate of 25% whilst the
median OS among patients with ED is 8–13 months with a 2-year poor survival rate of roughly 5%
with standard treatment [5,7–9].
Unlike non-squamous non-small-cell lung cancer (NSCLC), SCLC is characterised by a lack of
mutually-exclusive, targetable, oncogenic driver mutations [10,11]. Inactivating mutations in the
tumour suppressor protein p53 gene (TP53) and retinoblastoma 1 gene (RB1) are the most common
recurring mutations in SCLC that cannot be targeted directly [12,13]. Over the last two decades,
there has been swift progress in the understanding of the molecular biology of NSCLC and the
development of molecular targeted therapy, yet traditional chemo- and radiation therapy for SCLC has
remained unchanged [14,15]. Therefore, to improve the treatment outcome of SCLC patients, novel
strategies are immediately necessary.
The current successes of cancer-targeted immunotherapies in numerous kinds of cancers have
revitalised the hope for better SCLC treatments [15]. Among these greatest successes has been the
development of immune checkpoint inhibitors (ICIs), antibodies against programmed death-1 (PD-1),
and its ligand, (PD-L1). In cancer tissues, PD-1 is upregulated on tumour-infiltrating lymphocytes
(TILs), while PD-L1 is expressed on many types of cancer cells. Cancer cells express PD-L1 to escape
immune surveillance via ligation to PD-1 expressed in an adaptive immune response. [16–18].
SCLC has been hypothesised to be an immunogenic disease due to the high prevalence of
paraneoplastic disorders among SCLC patients [19,20]. Also, the high somatic mutation frequency
of SCLC suggests that these tumours are more likely to be immunogenic and could respond to
ICIs due to greater variety of neoantigens that can prompt an anti-tumour immune response [21].
Clinical trials have demonstrated that blockade of the interactions between PD-1 and PD-L1 enhances
anticancer immunity in SCLC, thus leading to a potentially-improved progression-free survival (PFS)
and OS [22–24]. This led to the FDA approval of nivolumab, a fully humanised PD-1 ICI antibody,
as a third-line treatment for recurrent SCLC in 2018; and of atezolizumab, a fully humanised PD-L1 ICI
antibody, as first-line treatment in combination with chemotherapy for extensive diseased staged SCLC
(ED-SCLC) in 2019 [25,26]. More recently, durvalumab, a humanised PD-L1 ICI antibody, was also
approved in combination with chemotherapy as a first-line treatment for ED-SCLC [27]. The observed
clinical benefits in these clinical trials have not been staggering, with a survival benefit of only 2 months
and 3 months alongside the addition of ICIs to chemotherapy Hence, biomarkers are needed in the
SCLC patient group to help determine who will experience clinical benefit as ICIs have been recognised
as a standard treatment option for SCLC.
Several recent studies have determined the expression of PD-L1 protein in SCLC with a range
of 0.0–82.8% PD-L1-positive detection rates [28–34]. Nevertheless, their conclusions are limited
due to sample size, antibody clone utilised, staining pattern (membranous and/or cytoplasmic) and
cut-off values. In addition, a consistent issue is restricted access to large size and good quality
biopsies given that neither repetitive tumour biopsies nor surgical resection are standard of care for
SCLC [35]. Additionally, the juxtaposition of the lesions to large blood vessels produces potential
complications for trans-thoracic biopsies. These complicating factors have hindered the feasibility of
further investigating PD-L1 immunohistochemistry to identify SCLC patients who would benefit from
ICIs during treatment [36].
Since anti-PD-1/PD-L1 therapy has been approved for the treatment of SCLC, up-to-date and
accurate documentation of PD-L1 expression prevalence is needed to determine if it can serve as a
predictive biomarker. Although previous studies have reported on the prevalence of PD-L1 expression
in tumour cells for SCLC, there is no comprehensive meta-analysis of the prevalence of PD-L1 expression
in SCLC. Here, we performed a meta-analysis on studies conducted to evaluate the prevalence of the
expression of PD-L1 on tissue specimens from patients with SCLC and association with OS.
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2. Materials and Methods
2.1. Search Strategy and Selection Criteria
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [37], an online search of literature on PD-L1 expression in SCLC was conducted (Figure 1).
The databases searched were the National Center for Biotechnology Information (NCBI) PubMed,
Google Scholar, Cochrane Library and EMBASE. All literature searches were performed between
1 November 2019 and 21 May 2020 and were limited to studies conducted in English. The study
detailed search parameters that are attached to this manuscript as supplementary figures (Figure S1).
Different variations of search text were used in literature with each being an appropriate combination
of SCLC-tumour- and PD-L1-associated terms collectively (‘SCLC biopsied tumours’, ‘SCLC resected
tumours’, ‘programmed death ligand-1’, ‘programmed cell death ligand-1’, ‘PD-L1’, ‘CD274’ or
‘B7-H1’), disease terms (‘small-cell lung cancer’, ‘SCLC’, ‘small-cell lung malignancy’, ‘small-cell lung
neoplasm’ or ‘neuroendocrine carcinoma’) and a combination of terms.
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2.2. Eligibility and Selection of Articles and Data Extraction
Titles and abstracts of articles were reviewed independently by two authors, strictly using the
inclusion criteria stated below. There were yes/no questions for the abstract/title screening process.
If all questions were answered yes (or maybe), the article was included for full-text review. The yes/no
questions were: (1) Did the study assess the positivity of PD-L1 expression in tumour cells among SCLC
patients? (2) Did the study evaluate PD-L1 expression positivity rate and/or clinical outcomes (OS)?
(3) Did the study provide a risk analysis of association with clinical outcomes? Articles were excluded
upon full-text assessment if they did not meet the criteria. Information extracted from the selected
articles included authors’ names, year of publication, sample size, stage of the disease, antibody clones,
immunohistochemistry evaluations, PD-L1 positivity rates, cut-off values and prognostic value of
PD-L1 expression if it was reported (Table 1). Because this review was to assess the prevalence and/or
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the prognostic value of positive PD-L1 expression in SCLC, special consideration was given to letter to
the editor articles that met the inclusion criteria. The Newcastle–Ottawa Scale (NOS) [38] was used to
rate and assess the quality of the full-text articles included in the meta-analysis (Figure S2).
2.3. Data Analysis
All data were entered into Microsoft Excel and imported in R software version 3.5.3 for statistical
analyses. To minimise the effects of studies with extremely high or low prevalence estimates on the
overall pooled estimate, the Freeman–Tukey double arcsine transformation (PFT) was used before
pooling. A 95% confidence interval was used in assessing the individual study proportion and
pooled effects. The pooled estimates of the prevalence of PD-L1 expression were calculated by the
random-effect model. Evaluation of heterogeneity between studies was conducted using Cochran’s
heterogeneity statistics (Q) (chi-squared test; χ2) and the degree of inconsistency (I2).
Heterogeneity (I2) in the measure of association across studies was further quantified with
the I2 statistic, with a value of <25% indicating low heterogeneity, 25–50% indicating moderate
heterogeneity, 50–75% indicating high heterogeneity and >75% indicating extreme heterogeneity [39].
The robustness of the pooled effects and possible outliers were evaluated with the leave-one-out
sensitivity analysis. A subgroup analysis was performed to explore the possible heterogeneity among
studies. The publication bias was assessed using Begg’s funnel plots and confirmed by Egger’s test [40].
3. Results
A total of 2923 published articles was identified through the database search. Titles and
abstracts/summaries of these articles were screened for significance, and 2894 were excluded by
the condition of duplication, reviews, comments, incomplete data and case studies leaving 29 articles
to examine for eligibility. Two clinical trial studies that did not report on the detection rate of PD-L1
expression were excluded [41,42]. Paz-Ares et al. [43] and Reck et al. [44], included in this meta-analysis,
were further reports from clinical trials that did not initially report on PD-L1 expression. The primary
publications of these trials were excluded from the review and meta-analysis. A total of twenty-seven
published studies were included in the analysis to address the prevalence and/or prognostic value of
positive expression of PD-L1 in SCLC tumours. The steps used in acquiring the published articles
included in this review are depicted in Supplement Figure S3 following the PRISMA chart.
Table 1 shows a summary of the publications and details included in the metanalysis. All studies
were published between 2015 and 2019, with fifteen of them published between 2018 and 2020.
The sample size of the included studies ranged from 30 to 277 SCLC patients with a combined
sample size of 2792 SCLC patients. All studies employed immunohistochemistry for measuring and
evaluating PD-L1 expression except Carvajal-Hausdorf et al. who utilised multiplexed quantitative
immunofluorescence (QIF) for PD-L1 expression measurement and assessment [45]. The most common
PD-L1 antibodies used across the studies were clone 22C3 (n = 6) and clone E1L3N (n = 6) followed
by clone SP142 (n = 3), clone 28.8 (n = 3), clone 2B11D11 (n = 3), clone EPR1161 (n = 2), clone SP263
(n = 2), clone 5H1 (n = 1) and MAB1561 (n = 1), respectively (Table 1). The studies were conducted in
various region of the world with the majority of the studies (n = 15) coming from Asia, specifically,
China (n = 7), followed by Japan (n = 6), United States (n = 5), Italy (n = 2), multi-nationals (n = 3) and
one from each of the following countries—Germany, Italy, South Korea and Taiwan.
Twenty studies retrospectively assessed the expression of PD-L1 in SCLC tumour cells while
seven studies were clinical trials that reported the prevalence of PD-L1 expression in tumours.
More than half of the studies (n = 12) used both limited- and extensive-staged SCLC patients,
eleven had only extensive-staged patients while two studies constituted only limited-stage SCLC
patients. Twelve studies correlated PD-L1 expression with clinical outcomes including OS. Ten of these
studies provided statistical analysis on the high-risk association (hazard ratio; HR) with OS, with two
demonstrating statistically-significant difference in median OS (mOS) probabilities [28,34].
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Table 1. Prevalence of programmed death ligand-1 (PD-L1) on tumour cells in SCLC.
References




mOS, HR and p-Value)
Ott et al. 2017 [23]
(n = 145)
Biopsy tissue (n = 132)
Fresh tissue (n = 12) Extensive
Clone 22C3 antibody (Merck & Co,
Kenilworth, NJ, USA) Membranous ≥ 1% 31.7% (46/145) n/a
Antonia et al., 2016 [25]
(n = 213) Biopsy tissue Extensive
Clone 28-8; Epitomics Inc, Burlingame,
CA, USA) Membranous ≥ 1% 11.3% (24/213) n/a
Yu et al., 2016 [28]
(n = 249) Biopsy tissue
Extensive (n = 96)
Limited (n = 98)
Clone SP142 Dako clone 28.8 pharmDx
kit Membranous ≥ 1% 16.5 (41/245)
≥1% PD-L1/TPS,
mOS: 9.87 vs. 16.13 months,
Log rank test p = 0.0511
HR = 0.44 (95% CI
0.18–1.07, p = 0.055





Clone E1L3N (Cell Signalling
Technology, Cambridge, UK),
E1LN–membranous
Allred, ≥1%, ≥5% 22.5%, 27.5% 35.0% N/E
Clone 28.8 (Abcam Cambridge, UK)







15.%, 15.0%, 15.0% N/E
Miao et al., 2017 [30]
(n = 83) Biopsy tissue
Extensive (n = 36)
Limited (n = 47)
Clone 2B11D11/PD-L1/CD274 antibody,
Clone SP66, SPRINGBIO, USA)
Membranous and/or
cytoplasmic ≥ 5% 51.8% (43/83)
≥5% PD-L1/TPS (mOS, 17.0
vs. 9.0, Log rank test
p = 0.018)
HR not provided
Komiya and Madan, 2015
[31] (n = 99) Unknown n/a EPR1161 (Abcam, Cambridge, UK)
Membranous and/or
cytoplasmic ≥ 5% 82.8% (82/99) NE




Biopsy (n = 43)
Extensive (n = 49),
Limited (n = 49)
Clone 5H1 (Lieping Chen Laboratory,
Yale University, New Haven, CT, USA)
Clone E1L3N (Cell Signalling
Technology, Cambridge, UK)
Membranous ≥ 1%, 0.0% (0/94) NE
Yasuda et al., 2018 [33]
(n = 39) Biopsy tissue Extensive
Clone 22C3 pharmDX (Agilent
Technologies, Santa Clara, CA, USA)
22C3 (Dako, Carptintera, CA, USA)
Membranous ≥ 1% 2.5% (1/39) N/E
Ishii et al., 2015 [34]
(n = 102) Biopsy tissue
Extensive (n = 61),
Limited (n = 41) EPR1161 (Abcam, Cambridge, UK)
Membranous and/or
cell-surface ≥ 5% 71.6% (73/102)
≥5% PD-L1/TPS
mOS: 16.3 vs. 7.3 months
Log-rank test p < 0.001
HR not provided
Pas-Ares et al., 2019 [43]
(n = 277) Biopsy tissue Extensive Clone SP263 Ventana PD-L1 Assay Membranous ≥ 1% 5.1 (14/277) n/a
Reck et al., 2020 [44]
(n = 137) Biopsy tissue Extensive Clone SP263 Ventana PD-L1 Assay Membranous ≥ 1% 5.8 (8/137) n/a
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n/a Limited (n = 23)Extensive (n = 32)
Clone E1L3N (Cell Signalling
Technology, Cambridge, UK),
Membranous and/or
cytoplasmic ≥ 1% 7.3% (4/55) NE
Chang et al., 2017 [46]
(n = 186) Biopsy tissue
Limited (n = 74)
Extensive (112)
Clone 2B11D11, PD-L1/CD274 antibody
(Cat/no.66248-1-Ig) Proteintech Group
Inc Chicago, IL, USA
Membranous ≥ 5% 78.0% (145/186) HR = 0.17 (95% CI:0.08–0.35, p < 0.001)




Limited (n = 25)
Extensive (n = 31)
Clone E1L3N, diluted 1:100; #13684,
Cell Signalling Technology) Membranous ≥ 5% 39.3% (22/56)
Overall survival (OS) ≥ 5%
HR = 0.37(95% CI:
0.21–0.68), p = 0.002




Clone E1L3N (Cell Signalling
Technology, Cambridge, UK), Membranous ≥ 5% 18.9% (14/74)
Lung-cancer-specific




HR = 0.19(95% CI:
0.10–1.30, p = 0.150)
Tsuruoka et al., 2017 [49]
(n = 65) Biopsy/cytology Limited
Clone E1L3N (Cell Signalling
Technology, Cambridge, UK), Membranous ≥ 1% 5.8% (4/65)
≥1% PD-L1/TPS, mOS (38
vs. 140 months)
Log rank test p = 0.067)
HR= 0.65(95% CI: 0.16–2.71,
p = 0.557)




Biopsy tissue (n = 66)
Limited (n = 66)
Extensive (n = 38)
Clone 22C3 (Dako, Carptintera,
CA, USA) Membranous ≥ 1% 25.0% (26/104) NE
Berghoff et al., 2016 [51]
(n = 32) Biopsy tissue Extensive
Clone 5H1 (Lieping Chen Laboratory,
Yale University, USA) (Dako,
Glostrup, Denmark)
Membranous ≥ 5% 34.4 (11/32)
≥5% PD-L1/TPS
mOS: 8 vs. 7 months
Log rank test p = 0.662
HR not provided
Gadgeel et al., 2018 [52]
(n = 30) Biopsy tissue Extensive
Clone 22C3 antibody (Dako, Carpinteria,
CA, USA). Membranous ≥ 1% 10.0% (3/30) n/a
Kim et al. 2018 [53]
(n = 120) Biopsy tissue
Limited (n = 39)
Extensive (n = 81)
MAB1561/B7-H1/PD-L1 antibody (R&D
Systems, Minneapolis, MN, USA Membranous ≥ 1% 14.2% (17/120)
≥1% PD-L1/TPS,
mOS: 12.0 vs. 18.0 months,
HR = 1.15 (95% CI
0.76–1.73, p = 0.510
Wang et al., 2018 [54]
(n = 94) Biopsy tissue Extensive (n = 52) Clone SP142; ZSGB-BIO, Beijing, China
Membranous and/or
cytoplasmic ≥ 5% 51.1% (48/94) NE
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mOS, HR and p-Value)
Ichiki et al., 2018 [55]
(n = 46) Surgically-resected
Limited (n = 12)
Extensive (n = 34)
Clone E1L3N, 1:800, Cell Signalling
Technology, Inc., Danvers, MA, USA) Membranous ≥ 1% 26.1% (12/46)
Overall Survival (OS):
HR = 0.98 (0.94–1.02),
p = 0.268
Liu et al., 2018 [56]
(n = 80) Surgically-resected Limited (n = 80)
Clone SP142 (cat. no. 07309554001; 1:100;
Spring Bioscience Corporation,
Pleasanton, CA, USA
Membranous ≥ 5% 65.0% (52/80)
Overall survival (OS) ≥ 5%
HR = 0.49 (95% CI:
0.28–0.85), p = 0.0110
Chung et al. 2018 [57]
(n = 107) Biopsy tissue Extensive
Clone 22C3 pharmDx assay
(Agilent Technologies) Membranous ≥ 1% 39.0% (42/107) n/a
Xu et al., 2019 [58]
(n = 60) Surgically-resected
Limited (n = 20)
Extensive (n = 40)
Clone 2B11D11 PD-L1/CD274 antibody
(cat. no. 66248-1-Ig) (ProteinTech Group,
Inc., Chicago, IL, USA)
Membranous and/or




Log rank test p = 0.781)
HR = 2.55 (95% CI:
01.18–5.51), p = 0.017
Zhao et al., 2019 [59]
(n = 155) Surgically-resected
Limited (n = 52)
Extensive (n = 103) Clone 22C3, PharmDx Membranous ≥ 1% 12.9% (20/155)
≥5% PD-L1/TPS,
mOS (12 vs. 57 months,
Lo g rank test p = 0.007)
HR= 5.30 (95% CI:
1.45–19.28), p = 0.011
Pujol et al., 2018 [60]
(n = 54) Biopsy tissue Extensive
SP142 PD-L1 immunohistochemistry
assay (Ventana Medical Systems, Inc.,
Tucson, AZ, USA)
Membranous ≥ 1% 1.8% (1/54) n/a
IHC, immunohistochemistry; QIF, quantitative immunofluorescence (QIF); SCLC, small-cell lung cancer; HR, hazard ratio; N/P, not provided in the article; KM, Kaplan–Meier; OS, overall
survival; mOS, median overall survival; TPS, tumour proportional score; NE, prognostic or predictive significance not evaluated; n/a, not applicable.
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3.1. Prevalence of PD-L1 Expression in SCLC
The prevalence of PD-L1 expression in SCLC was retrieved from all 27 publications included.
PD-L1 positivity was defined by tumour proportional score (TPS) and combined proportion score (CPS).
Three of the 27 articles used CPS while the rest employed TPS to define positive PD-L1 expression.
One study that assessed positive PD-L1 expression by comparing different antibodies, to minimise
the effect of this study on the pooled estimates of PD-L1 expression prevalence, the detection rate
recorded by the 28.8 PD-L1 antibody assay was used in the metanalysis [29]. The reported prevalence
of PD-L1 expression in these studies ranged from 0.0 to 82.8%. The pooled estimate of the prevalence of
PD-L1 expression in SCLC was 26.0% (95% CI: 16.9.0–37.5). The observed effect size was significantly
heterogeneous (I2 = 97.4, 95% CI: 95.5–98.5, p < 0.0001) (Figure 2).
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are represented with tal line and the square area mi rors the point es imate of each study.
A r o -effect model was utilised.
We performed the leave-one- i ity analysis to identify the outlying studies that h d a
potential influence on the eff ct size of the forest plot. Four studies including Komiya and Mad n, 2015;
Schultheis et al., 2015, Ishii et al., 2015 and Chang et al., 2017 [31,32,34,46] had a more pronounced
impact on the pooled estimated prevalence of PD-L1 expression. Represented boxes deviated further
from the reference line (Figure 3). After the potential outlying studies were left out of the random-effect
model, the pooled estimate of the prevalence of PD-L1 expression in SCLC was 22.0% (95% CI: 15.0–30.0)
with a significant heterogeneity (I2 = 95.0, 95% CI: 91.6–97.5, p < 0.0001) (Figure S4).
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values of ≥5% and ≥1% membranous or me branous and cytoplasmic stai ing of the tumour cells.
Studies that employed a cut-off of ≥5% recorded a higher pooled estimate of the prevalence of PD-L1
expression (56.0%, 95% CI (45.0–67.0%)) with significant heterogeneity (I2 = 94.0% p < 0.01) than those
that used a cut-off value of≥1% (12.0%, 95% CI (7.0–19.0%); I2 = 91.0% p < 0.01). A statistically-significant
difference between ≥5% and ≥1% IHC cut-off values for pooled estimates was observed based on the
test of moderators (QM) (QM (1) = 45.8, p < 0.0001) (Figure 4).
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Further subgroup analysis reveals that used FDA approved PD-L1 antibody had lower pooled
estimates compared to those that did not use (19.0.0%, vs. 35.0). However, there was no significant
difference in the pooled estimate on the prevalence of PD-L1 expression (QM (1) = 2.69, p = 0.1008)
(Figure S5).
Cells 2020, 9, 2393 13 of 22
Articles were classified based on geographical regions (Asia and others). Articles carried out in
Asia observed a high pooled estimate compared to articles from other regions irrespective of the cut-off
values for PD-L1 staining with a significant difference between the two groups for PD-L1 prevalence
(36.0% vs. 16.0%, QM = 4.46, p = 0.0347) (Figure S6).
A meta-regression analysis demonstrated that a unit increases in the study’s sample size
affects a 0.2% decrease in the detection rate of PD-L1 expression. However, sample size was not a
statistically-significant moderator of the pooled estimated prevalence of PD-L1 expression (QM (1) = 0.27,
p = 0.6008), which was evident by the insignificant regression constant (R2 = −0.002, p = 0.6008).
However, it was noted that studies with a smaller sample size had low detection rates (Figure S7).
Another meta-regression plot significantly shows that the poor-quality studies tend to have higher
Fisher’s Z scores of the effect sizes. In contrast, the better quality studies tend to have lower scores
(QM (1) =6.99, p = 0.0082, R2 = 0.059, p = 0.0082), indicating that quality of a study is an important
moderator of the pooled estimate of the prevalence of PD-L1 expression in SCLC (Figure S8).
3.2. Effect of PD-L1 Expression in Survival
Overall, ten clinical studies stated HR values and 95% confidence intervals (CIs). Nine of these
reported HR values and CIs to evaluate positive PD-L1 expression with OS. Only Chang et al. reported
HR value and CI for negative PD-L1 expression. Individually, six studies showed PD-L1 to be associated
with better overall OS with two studies recording statistical significance. Three studies demonstrated a
statistically significant association of PD-L1 expression with shorter OS.
The estimated pooled HR for nine studies was calculated utilising a random-effect model because
the heterogeneity across studies was statistically-significant (χ2 =34.3, p < 0.001, I2 = 88.7%). The pooled
HR of all studies was 0.86 (95% CI: 0.49–1.50, p = 0.5880) indicating that positive PD-L1 expression
showed a trend towards longer OS in SCLC patients (Figure 7). The Egger test demonstrated that
Begg’s funnel plot was insignificantly asymmetrical (p = 0.7944) (Figure S9).
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4. Discussion
The potential of applying ICIs for the treatment of SCLC became apparent after the promising
results observed in non-small-cell lung cancer, melanoma and other cancer subtypes [61]. High tumour
mutational burden has been associated with response to ICIs in several tumours including
NSCLC [62,63]. SCLC is a carcinogen-related cancer, with a high frequency of mutation per megabase
(7.37 mut/Mb) [11,63,64]. It is, therefore postulated, that SCLC islikely to respond to ICIs because
a high variety of neoantigens can prompt an immune-mediated response [62]. This instigated the
pursuit of anti-PD1/PD-L1 treatments for SCLC, independent of PD-L1 expression.
The present study provides a systematic review and meta-analysis of PD-L1 expression in SCLC.
The pooled prevalence of the expression of PD-L1 in SCLC tumours is 26.0%, and 22.0% after removal
of potential outlying studies. However, there were large differences in the rate of PD-L1 expression
in SCLC tumours between the studies included, varying from 0% to 82.8%. For instance, Ishii et al.
reported a high PD-L1 expression rate while Schultheis et al. showed that PD-L1 expression was absent
in SCLC tumour cells (71.6% vs. 0.0%). This discrepancy is due to different clones of antibodies and/or
scoring systems. Additionally, Ishii et al. restricted their study population to SCLC patients whose
tissue specimens were obtained principally from primary tumours (81.4%), thus presumably most
specimens were collected through biopsies. Conversely, Schultheis et al. show that majority of the
specimens were derived via resection (54.0%) [32,34]. With the exclusive use of resected specimens,
it is possibly biased as only a small percentage of SCLC tumours get resections, notwithstanding that
they are in a better prognosis group. On the other hand, the exclusive use of resected samples may
minimise sampling error if PD-L1expression on both tumour and immune cells is considered in the
scoring algorithm. Overall, the observed pooled prevalence of PD-L1 expression in tumours is lower
compared to what has been reported for non-small-cell lung cancer (NSCLC) [47,65–67].
Due to the presence of substantial heterogeneity, further analyses were warranted to identify
potential factors that can explain the inconsistencies between pooled estimates across studies.
Factors such as whether an FDA-approved PD-L1 antibody was used or not did not provide a
significant effect on the overall pooled estimated PD-L1 prevalence in SCLC in these studies. Also,
meta-regression analysis did not show any significant association between sample size and the pooled
estimated prevalence of PD-L1 expression.
However, the application of sub-analysis indicated that IHC evaluation cut-off values (≥1% and
≥5%) had a significant moderating effect on the pooled prevalence estimates, and that could underscore
the true heterogeneity in the pooled estimates of PD-L1 prevalence in this meta-analysis. Studies that
employed a cut-off of ≥5% recorded a higher pooled estimate of the prevalence of PD-L1 expression
compared to those that used a ≥1% cut-off for PD-L1 IHC evaluation. This association between high
cut-off score and high detection rates, seems, at first sight, counterintuitive, but it might be the result of
the investigators adapting their cut-off given the intensity and prevalence of PD-L1-expressing cells in
their analysis. For instance, Tsuruoka et al. and Inamura et al., employed the same antibody for PD-L1
staining and used different cut-off values for PD-L1 positivity with Inamura et al. having a higher
detection rate [48,49].
Currently, there are separate scoring systems for PD-L1 staining in NSCLC tumour cells with four
FDA-approved PD-L1 assays (antibodies: 22C3, 28.8, SP263 and SP142) on two different platforms
(Dako, Ventana) [68–72]. Twelve out of the 25 studies included in this review exclusively used
commercially-available FDA-approved PD-L1 antibodies. Only Takada et al. used three different
PD-L1 antibodies (28.8, SP142 and E1L3N), of which two are FDA-approved, in a study that
immunohistochemically analysed PD-L1 expression in surgically-resected SCLC [28,29]. The remaining
12 studies did not use FDA-approved PD-L1 antibodies; two of these studies reported a high expression
of PD-L1 using antibodies utilised that been discontinued due to the lack of specificity for PD-L1 [31,34].
We observed that studies that did not use FDA-approved PD-L1 antibodies recorded high prevalence for
PD-L1 expression, compared with those that utilised the FDA-approved PD-L1 antibodies. However,
this difference was not statistically significant. Nevertheless, the detection rates of PD-L1 expression
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were coherent among studies employing FDA-approved assays with the same staining pattern and
cut-off values [31,34].
There have been multiple reports indicating that the positivity of PD-L1 definitions is not the
same for the different approved and commercially-available PD-L1 assays [73–76]. In three of the
FDA-approved PD-L1 assays, 28.8, SP263 and 22C3, the positivity of PD-L1 staining is defined as
complete-circumferential or partial-linear plasma membrane staining of tumour cells at any intensity.
Most antibodies to PD-L1 in use are directed to its extracellular domain and immunohistochemically
stain tumour tissue with a mixture of cytoplasmic and membrane staining. Cytoplasmic staining
obscures the interpretation of a positive reaction on the tumour cell membrane, and thus affects
the accuracy of PD-L1 scoring. For scoring purposes, cytoplasmic staining in tumour cells is not
considered positive [73–75]. On the other hand, PD-L1-positive immune cells, as well as the tumour
cells, are considered in the criteria of positive PD-L1 staining in the use of SP142 antibody clone [76].
Unsurprisingly, in our findings, the pooled estimates for PD-L1 expression among studies that use
SP142 PD-L1antibody assay were higher than pooled estimates from those that used 22C3 and
28.8 PD-L1 antibody assays. Additionally, the results of the test for heterogeneity in our meta-analysis
indicated that the PD-L1 staining pattern criteria, membranous alone vs. membranous and cytoplasmic,
significantly explained the variation in the pooled estimate of the prevalence for PD-L1 expression.
To some extent, this hinders the attempt to establish one PD-L1 IHC test and contributes to the
inconsistencies across studies.
A comparative study, (Blueprint phase I and II projects) to assess the feasibility of harmonising the
clinical use of these independently-developed commercially- and FDA-approved PD-L1 IHC assays
for PD-L1 detection has been conducted for NSCLC. Both phases I and II of the Blueprint project
demonstrated that three (28.8, 22C3 and SP263) of the four assays can be used interchangeably for NSCLC
tumour staining whereas the fourth (SP142) constantly stained fewer tumour cells [71,72]. Notably,
results from the phase I of the Blueprint project revealed that the detection rates of PD-L1 expression
were 60.5%, 60.5% 78.9% and 52.6% for clones 28.8 (1%TPS), 22C3 (1% TPS), SP142 (TC1+/-IC1) and
SP263 (25%TPS), respectively [71,72]. These findings are congruent with our meta-analysis results
taking into consideration that the expression of PD-L1 has been reported to be proportionally low in
SCLC in most studies compared to PD-L1 expression in NSCLC [25,74,77,78]. Specifically, the low
detection rates observed for both clones 28.8 and 22C3 (60.5%) in comparison with a high detection
rate for SP142 (78.9%) in the Blueprint project, are consistent with the pooled estimates recorded for
clones 28.8 (18.0%), 22C3 (19.0%) and SP142 (35.0%) in our meta-analysis results.
Unlike in NSCLC, there has been no large scale ‘harmonisation’ study to examine the performance
of different PD-1 IHC tests on the same specimens of SCLC patients. There is a need for studies such as
the Blueprint projects for evaluation of PD-L1 expression in SCLC tumours among a large cohort of
patients. As a first step, Takada et al. in their study conducted detailed PD-L1 expression analyses in
surgically-resected specimens utilising different antibodies and positive cut-off values. The authors
also carried out an exhaustive evaluation not only for tumour cells but also for immune and tumour
cells together [29].
High expression of PD-L1 has been observed in several solid tumours and previous studies have
demonstrated a statistically significant association of PD-L1 expression with response to PD-1/PD-L1
therapies in previously-treated patients with advanced NSCLC [79–81]. Moreover, several studies
have concluded that high expression of PD-L1 in tumours was associated with shorter survival
in meta-analyses of PD-L1 expression in NSCLC [81,82]. On the other hand, our meta-analysis
indicates that positive expression of PD-L1 appears to confer longer OS of SCLC patients. While this
correlation was not statistically significant, it was consistent with previous reports [47,83]. Zhang et al.
2017 reported that PD-L1 expression was a poor prognostic indicator for NSCLC and pulmonary
lymphoepithelioma-like carcinoma (LELC) but not for SCLC [83]. Moreover, the observed longer
survival benefits could also be due to the fact that four out of the nine studies that assess the association
between PD-L1 expression and OS in this meta-analysis recruited limited-stage SCLC patients while
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the rest enrolled both limited- and extensive-staged SCLC patients. The prevalence of PD-L1 expression
in patients with NSCLC ranges from 50% to 70%, however, the expression of PD-L1 has been reported
to be proportionally low in patients with SCLC with most studies demonstrating less than 50% PD-L1
expression. Previous studies have reported that PD-L1 expression in SCLC tends to be lower in
advanced disease stages compared to earlier disease stages [50]. For the most part, it is evident
in the literature that positive expression of PD-L1 occurs more frequently on tumour-infiltrating
immune cells within the SCLC, compared to PD-L1 expression on tumour cells, and high PD-L1
expression on the infiltrating immune cells has been associated with favourable clinical outcome in
SCLC patients [28,51–53].
There are several limitations to the current study that should be noted. Most of the studies included
in the review and meta-analysis are retrospective in nature and have relatively-small sample sizes.
Analytical factors such as the type of specimen used for analysing PD-L1 expression (biopsy specimen
vs. excision specimen), the use of different assays to assess PD-L1, varied cut-off values, different
scoring algorithms (tumour proportional scores vs. combined proportion scores) and the pattern of
staining (membranous vs. cytoplasmic) for PD-L1 positivity assessment, significantly varied between
studies. Finally, outcome readouts can be influenced by the lack of standardisation of treatment
regimens, which may affect survival. Although we perform subgroup analysis and meta-regression,
it quite possible that unidentified factors contributed to the significant heterogeneity persisting in the
results. The real heterogeneity can be ascribed to methodological and/or clinical variation, specifically
systemic diversities between studies beyond what would be expected by chance, such as sample
characteristics, study settings, study designs and interventions, and any combination of such factors.
Therefore, data results should be generalised and interpreted with caution.
Ultimately, the main goal is to evaluate whether PD-L1 expression as a predictive biomarker
to select SCLC patients that will benefit from immunotherapy. However, tumour tissue is needed
to carry out this test. Fine-needle aspiration only provides a limited amount of tumour sample for
diagnostic analysis, which commonly is not adequate for molecular testing or to accurately assess
PD-L1 expression by IHC and has high background stromal cells [84,85]. Moreover, the mutational
status of tumours may be altered during therapy which necessitates the need for consecutive samplings.
But then again, re-biopsy after initial therapy is not always possible in SCLC patients [86,87].
It is anticipated that circulating tumour cells (CTCs) can serve as a non-intrusive, episodically,
and real-time substitute for tumour biopsies for assessing PD-L1 expression in SCLC in the future.
SCLC is distinguished by having a larger number of CTCs in extended and recurring diseases compared
to other carcinomas [88,89]. Recent studies have demonstrated how the expression of PD-L1 in CTCs
could be employed to identify patients with NSCLC for anti-PD-1/PD-L1 therapy [90–93]. Moreover,
the expression of PD-L1 evaluated using CTCs could represent the sum of metastatic sites within a
patient, which might overcome the heterogeneity of PD-L1 expression.
5. Conclusions
The evidence from this study suggests that there are differences in the prevalence of PD-L1
expression in SCLC tumour cells across studies. The pooled prevalence of PD-L1 expression is lower
compared to what is reported in NSCLC and is significantly influenced by IHC evaluation cut-off values,
assessment of PD-L1 staining pattern and the quality of the study’s methodological characteristics.
Although positive PD-L1 expression in SCLC appears to confer better OS in SCLC patients, its use as
prognostic index warrants further studies due to significant variations. Given the prospect of PD-L1
evaluation to impact clinical outcomes of SCLC patients treated with ICIs, there is a need for large,
longitudinal, multicentre studies with well-defined protocols and endpoints to advance the clinical
value of PD-L1 expression.
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Figure S1. Search strategy-PubMed/Scopus; Figure S2. Assessment of the quality of methodological characteristics
on included studies utilising the Newcastle–Ottawa Scale (NOS); Figure S3. Begg’s funnel plots for publication bias
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rate of PD-L1 expression in SCLC after the leave-one-out sensitivity analysis to remove outliers; Figure S5. Forest
plot of subgroup analysis of the association between the use of FDA-approved PD-L1 assays or not and prevalence
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distribution of published articles and prevalence of PD-L1 expression; Figure S7. Meta-regression plot showing the
association of sample size with a pooled estimate of the prevalence of PD-L1 expression; Figure S8. Meta-regression
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PD-L1 expression; Figure S9. Begg’s funnel plots for publication bias testing for the prognosis of PD-L1 expression
in SCLC.
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